BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Ultragenyx Raises $15 Million Toward $30 Million Goal


7/31/2012 7:45:22 AM

San Francisco Business Times by Ron Leuty, Reporter

Orphan drug developer Ultragenyx Pharmaceutical Inc. has gathered $15.1 million toward a goal of raising $30.1 million, according to a Securities and Exchange Commission filing Monday.

The Novato company, started by former BioMarin Pharmaceutical Inc. Chief Medical Officer Emil Kakkis, has won orphan drug designation for two drugs from the Food and Drug Administration as well as from European drug regulators.

In the United States, the designation cuts FDA fees and allows tax credits for companies that develop drugs which treat diseases with 200,000 or fewer patients in the United States.

Ultragenyx said earlier this month that it started a mid-stage study of UX-001, its extended-release oral tablet for hereditary inclusion body myopathy. The rare neuromuscular disease is caused by a deficiency of sialic acid.

The company's other drug, UX-003, is designed as an enzyme-replacement therapy to treat a metabolic disorder called MPS7, also known as Sly disease or mucopolysaccharidosis type 7.

Ultragenyx's board includes representatives of venture capital firms TPG Biotech, HealthCap, Fidelity Biosciences and Pappas Ventures.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->